Summary The mapping of allelic loss on the short arm of chromosome 1 has been performed in non-small-cell lung cancer. We used a set of 11 
(NSCLC), have been revealed in oncogenes and tumour-suppressor genes (Carbone and Minna, 1992) . The most important findings concerning the last group are inactivation by deletions and/or point mutations of p53 (Chiba et al, 1990) , CDKN2/MTSl/pJ6INC4 (Washimi et al, 1995) and several regions on chromosome 3p (Houle et al, 1991; Gray et al, 1995; Roche et al, 1996) . Furthermore, several regions on lp, lq, 2q, 5q, 8q, Ilp, 12p, 13q, 18q and 22q have been reported to be frequently affected by recurrent loss of genetic material (Weston et al, 1989; Shiseki et al, 1994; Fong et al, 1995a; Takeuchi et al, 1996) . It may imply the presence of unknown tumour-suppressor genes of considerable importance on these chromosomes.
Cytogenetic analysis of NSCLC has shown a consistent deletion at lpl3 (Testa and Siegfried, 1992; Lukeis et al, 1993; Johansson et al, 1994) , although the use of cytogenetic analysis is complicated for these tumours because of a low mitotic index and extremely complex karyotypes with many additional chromosomes (Testa and Siegfried, 1992) .
Restriction fragment length polymorphism (RFLP) analysis has revealed allelic loss at lp32-35 in 14-18% of informative cases (Tsuchiya et al, 1992; Sato et al, 1994; Shiseki et al, 1994) . However, RFLP markers are of limited use because of 50% heterozygosity at any one locus (Hoggard et al, 1995) . Allelotyping using highly informative, well-distributed microsatellite markers may reveal more comprehensive data. For example, Fong et al (1996) have recently shown allelic loss at Alu VpA locus MYCLI (lp32) in 29% of informative NSCLCs.
Microsatellite sequences that are also disposed to instability appeared as either a substantial change in repeat length (often (Thibodeau et al, 1993) . Microsatellite instability (MI) has been identified as a novel genetic abnormality in tumours of patients with hereditary non-polyposis colorectal cancer syndrome (HNPCC) Thibodeau et al, 1993) and has been also reported in sporadic types of HNPCC-associated tumours of the colon, pancreas and stomach (Han et al, 1993; Peltomaki et al, 1993) . Although HNPCC-unrelated sporadic tumours of bladder, brain and lung have been shown to have a much lower frequency of MI (Gonzalez-Zulueta et al, 1993; Peltomaki et al, 1993; Fong et al, 1995b; Zhu et al, 1996) , controversial data for both small-cell and non-small-cell lung carcinomas have been published (Merlo et al, 1994; Shridhar et al, 1994) .
To date, a few allelotyping studies of chromosome lp in NSCLC have been performed, and the limited number of loci have been screened. The data about MI frequency for NSCLC are conflicting, and studies of microsatellite loci spanning chromosome lp are of great interest. We performed allelotyping of 11 microsatellite loci spanning the short arm of chromosome 1 in NSCLC patients with different clinicopathological parameters: age, sex, histological type of tumour, rate of cell differentiation, stage of disease, rate of relapse and metastatic manifestation after surgical operation. The two shortest regions of the overlap (SRO) of the deletions have been identified: SRO 1 at lpl3.1 and SRO 2 at lp32-pter. These regions may harbour tumour-supressor genes involved in NSCLC development. Microsatellite instability has been found infrequently at the loci tested. SqC   G3  G3  G2  G2  G2  G2  G2  G3  G2  G2  G2  G2  G3 7, 10, 12, 13, 16, 18, 21, 23, 27, 35, 40, 41, 54 . Group B, 1p21-pcen, include case nos 1, 29, 30, 45, 46, 50, 53, 58 . Group C, both named above regions, include case nos 3, 14, 15, 17, 19, 20, 24, 25, 28, 31, 36, 37, 38, 42, 43, 44, 47, 48, 51, 55, 57 British Journal of Cancer (1998) (1986) . DNA was extracted from tumour cells and lymphocytes using standard methods (Sambrook et al, 1989) .
MATERIALS AND METHODS
PCR and allelotyping studies
The allelotyping study was performed using PCR amplification of 11 microsatellite repeat polymorphisms (CA repeats, DIS514, DIS2881, DIS239, DIS236, DIS499, DIS417, DIS162, DIS247, DIS160, DIS243 (Dib et al, 1996) and Alu VpA repeat, MYCLI (Makela et al, 1992) ). The map positions are summarized in Figure  3 . Genomic DNA (100 ng) was amplified in a reaction mixture (50 gl), containing 1.5 mm magnesium chloride, 50 mM potassium chloride, 20 mm Tris-HCl (pH 8.4), 250 mm of each deoxynucleotide triphosphate, 150 ng of each primer and 0.4 U Taq polymerase (Perkin-Elmer/Cetus). PCR occurred after a 3-min initial denaturation at 95°C, with 35 cycles of 30 s each of denaturation at 95°C, 30 s of annealing at 55°C, and 45 s of elongation at 72°C. This was followed by a final extension step of 10 min at 72°C. A 3-,ul sample of the PCR product was mixed with 6 gl of loading buffer, consisting of 0.025% bromophenol blue, 0.025% xylencyanol FF and 97% formamide, denatured for 10 min at 100°C and immediately cooled in ice until electrophoresis. A 2-gl sample of mixture was loaded onto a 6% sequencing polyacrylamide gel and run for 6 h at 1780 V. Separated PCR products were then dry transferred onto Hybond N+ membrane (Amersham) and hybridized with (CA),, probe (for MYCLI -one of the PCR primers), end-labelled with [,y-32P]dATP by T4 polynucleotide kinase (Biolabs, US). Hybridization was carried out for 12 h at 42°C in a buffer containing phosphates (disodium hydrogen phosphate/sodium dihydrogen phosphate 0.13 M, sodium chloride 0.25 M, sodium dodecyl sulphate) (SDS) 7% and PEG 6000 10%. Filters were washed at room temperature twice during 10 min in buffer containing 0.1% SDS and 2 x standard saline citrate (SSC), exposed to radiograph film (XBM, Germany) with an intensifying screen at -70°C during 12-24 h.
Microsatellite imbalance was assessed visually by two independent observers. Cases that were difficult to interpret were analysed using a densitometer. LOH was considered to occur when the intensity of the allele in tumour DNA was approximately less than 50% of that in the corresponding normal DNA (Figure 2 ).
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Figure 2 Representative 
RESULTS
Paired tumour/normal DNA samples from 58 NSCLC patients were examined for allelic imbalance for microsatellite loci at the short arm of chromosome 1. The results are shown in Figure 1 . Clinicopathological characteristics have been compared with the allelic status of patients (Table 1) .
Loss of heterozygosity
Allelic imbalance or loss of heterozygosity (LOH) (Figure 2 ) occurred in at least one locus in 51 of 58 tumours (87.9%) (black boxes in Figure 1 ). High levels of LOH frequency (>40%) were found for seven loci (Figure 3) , DIS160 (lp36.2) and DIS243 (lp36.3). However, a significant difference (P < 0.05) or apparent trend towards significance (P < 0.1) in LOH frequency has been observed between loci at lpl3.1, lp32-pter and loci localized in the middle area of lp: DIS236 and DIS499.
To determine the shortest regions of overlap, the special approach was used (Bieche et al, 1993) . All cases of allelic loss may be classified on the basis of their location. We have supposed the entire or nearly entire (all informative loci were LOH affected with the exception of DlSS514) l p deletion in five cases only: nos 8, 9, 11, 22 and 26 (Figure 1 ). To take into account the absence of sufficient information for several cases, 42 cases with partial deletions and clear allelotype for most of the loci tested may be subdivided into three groups: A -with deletions at the distal part of lp (n = 13); Bwith deletions at the proximal part of lp (n = 8); and C -tumours with deletions at both these regions (n = 2 1). For example, in tumour no 3 loci DIS514, D1S239 at the proximal part of I p and four loci at the distal part of lp had lost one allele, whereas interstitial loci -DIS236, DIS499 remained heterozygous (see Figure 1) . Thus, case no 3 was included in group C. Alternatively, in cases no 7 and no 30, LOH was determined at one of these regions only, and these cases were included in groups A and B respectively. Analysis of groups B and C allows us to define the SRO, which included DIS514-DIS2881 (lpl3.1): 20 tumours had allelic loss at least at one of these loci and ten tumours had LOH at both loci. On the other hand, in groups A and C most tumours reveal a pattern of LOH consistent (Figures 1 and 3) .
We also analysed the relationship between LOH for both SROs and traditional clinicopathological parameters: age, sex, histological type, rate of cell differentiation and TNM classification (Table  1) . No significant difference has been observed in LOH frequency between adenocarcinoma and squamous cell carcinoma. On the other hand, LOH at SRO 2 has been significantly associated with biological evidence of tumour progression: lymph node involvement was found in 15 of 20 tumours with LOH, compared with 13 out of 33 cases without LOH (P = 0.022) ( Table 1 ). An apparent trend towards significance has been demonstrated between LOH at SRO 2 and tumours with the classification T3-T4 (P = 0.067). Finally, stage III-IV tumours have been affected more frequently at these regions than tumours from patients with stage I-II of disease (17 out of 30 vs 3 out of 22, P = 0.002). The same correlation has not been found for SRO 1. The association between LOH at SRO and progression of disease after surgical treatment was also analysed using the logrank test. The further development of disease in 37 patients was tracked not less than 2 years after operation. To analyse the association with respect to SRO 2, these patients were subdivided into two groups: those with big deletions involving lp32-36 (n = 17); and those with LOH at more proximal loci only (n = 20, Figure 4) . As SRO 1 is not big, 19 cases with LOH at DIS514 and/or DIS2881 only vs 17 cases with LOH at more distal loci were analysed with regard to tumour progression. Patients with LOH at SRO 2 had a more frequent post-operating metastatic manifestation and relapse than those without LOH (n = 20; X2 = 5.146, P = 0.023). We did not have the same association for SRO 1 (%2 = 0.83 1, P = 0.362). Thus, in contrast with SRO 2, deletions at SRO 1 have not been associated with advanced stage of disease.
Microsatellite instability
Six (10.3%) of 58 tumour samples have been detected that harbour MI in at least one locus (hatched boxes in the Table 1 ). This phenomenon appeared as either formation of the new allele or shifts of electrophoretic mobility at simple sequence tandem repeat loci (Figure 2) . MI was present at eight of the loci tested but not at DIS417, MYCLI and DIS247. MI was detected at DIS162 in three tumours, at D1S499 in two tumours and at other affected loci in one tumour. Four of the six patients with MI had lymph node metastasis British Journal of Cancer (1998) at the time of surgical intervention and one of six patients had stage I disease (P = 0.081). One patient (no. 6) harboured different types of MI at multiple loci (Figure 1) . Previously, we detected a mutant KRAS gene (codon 12) in case no. 6 out of 30 analysed (Yakubovskaya et al, 1995) . The findings indicate high genetic instability of this tumour. It must be stressed that tumour no. 6 was 10 x 10 x 12 cm and clinical classification T4N3MO.
DISCUSSION
Microsatellite markers are successfully used in allelotyping studies for the search of unknown TSGs that are involved in NSCLC development. Allelic losses at single loci on chromosome lp have been described (Tsuchiya et al, 1992; Sato et al, 1994; Fong et al, 1996) . In the present study, we have tried to perform detailed deletion mapping using 11 microsatellite loci spanning 1p in an effort to identify the SRO of the deletions where specific TSG(s) may reside.
Our results indicate allelic imbalance at all of the loci tested. The terms 'allelic imbalance', 'loss of heterozygosity' and 'allelespecific deletions' are used equally because cytogenetic studies have rarely shown lp amplification in NSCLC, whereas deletions have been found (Testa and Siegfried, 1992; Lukeis et al, 1993) . Furthermore, gene LMYC (lp32) is rarely amplified (< 1%) in these tumours (Yokota et al? 1988) .
We identified the two SRO of the deletions: SRO 1 between loci DJS514 and DIS2881 (lpll3.1), and SRO 2 between DIS162 and DIS243 (lp32-pter).
Previously in NSCLC, two loci on lp were tested using the RFLP technique: DIS57 (lp32-35) and MYCLI (last marker shapes by the EcoRI restriction site inside the proto-oncogene) (lp32). Sato et al (1994) and Tsuchiya et al (1992) reported LOH at DIS57 in 15-18% of informative cases. Although LOH at MYCLI was not shown in the initial study by Kawashima et al (1988) , Shiseki et al (1994) have since described this alteration in 14% of NSCLCs. A recent study of Alu VpA locus MYCLI, mapped 16 kb upstream of gene LMYC (Makela et al, 1992) , showed allelic loss in 29% of informative cases (Fong et al, 1996) . We have found more frequent LOH at this locus (40%). The discrepancies observed may be the result of relatively small numbers of informative cases in RFLP study and different numbers of patients with early and advanced stage in current and previous studies. Both these possibilities are probably because only 18-22 informative tumours were analysed in RFLP studies of MYCLI (Kawashima et al, 1988; Tsuchiya et al, 1992) . On the other hand, a close correlation was shown between LOH at Alu VpA locus MYCLI and advanced stage of disease (Fong et al, 1996) . In the present study, 30% of patients had early stage disease, whereas in two previous reports patients with this stage from 50-55% of analysed groups. Unfortunately, the impact of previous reports is limited because only a single locus was tested in each study.
Using several loci, we observed that a common deleted region is lp32-pter. Furthermore, LOH at SRO 2 correlates significantly with advanced TNM stage and post-operating progression of disease. These findings suggest that one or more crucial genes at this region may be involved in NSCLC progression. It is known that LMYC, JUN, BLYM, LCK and FGR oncogenes are located at SRO 2. Allele-specific deletion is not considered obligatory for direct oncogene activation. However, any deregulation (both up and down) of LMYC expression, for example, may be crucial for cell proliferation and differentiation (Hesketh, 1995) .
On the other hand, LOH on the distal part of chromosome lp has also been described in neuroblastoma (Fong et al, 1989; Martinsson et al, 1995) , malignant meningioma (Simon et al, 1995) , multiple endocrine neoplasia type 2 (Moley et al, 1992) and cancers of the liver (Kraus et al, 1996) , kidney (Schwerdtle et al, 1996) , colon (Leister et al, 1990) , pancreas (Ding et al, 1992) and breast (Bieche et al, 1993; Hoggard et al, 1995) . Correlation with the distal lp deletions in these cancers suggests that region lp32-pter harbours TSG(s) that may be involved in development of more than one tumour type. It is of interest that allelic loss at the distal part of chromosome 4 in mouse lung tumours localize a putative TSG to a region homologous with human chromosome lp34-pter (Herzog et al, 1995) . To date, in this region candidate TSGs include the CDK6 inhibitor p18 at lp32 (Guan et al, 1994) and the protein kinase gene complex PITSLRE at lp36 (Lanti et al, 1994) . Recently a new gene (p73) has been identified at the lp36 chromosomal region. This gene encodes a protein with significant amino acid similarity to the p53 tumour suppressor gene (Kaghad et al, 1997) . Moreover, p73 can activate the transcription of p53-responsive genes and inhibit cell growth in a p53-like manner by including apoptosis (programmed cell death) (Jost et al, 1997) . Possibly, the association between LOH at SRO 2 and poor prognosis of disease is due to p73 inactivation.
The SRO 2 is still quite large (on the other of 80 cM, see Figure  3 ), thus SRO 2 needs more precise deletion mapping. A test of deletions in SRO 2 may be useful in making individual disease development forecasts and it also may be used in complexes with already known molecular markers of non-small-cell lung cancer progression (Zborovskaya et al, 1996) .
Cytogenetic analysis has shown frequent structural rearrangements at lpl3 (Testa and Siegfried, 1992; Lukeis et al, 1993; Johansson et al, 1994) . Balanced translocations seemed to be relatively rare in NSCLC. In contrast, deletions and derivative chromosomes were often observed (Testa and Siegfried, 1992) . Using the molecular approach, we have found frequent allelic loss at lpl3.1 (SRO 1). Deletions at the same region were found in breast cancer (Bieche et al, 1993) . Oncogene NRAS is localized at lpl3. There are no data about its disregulation in NSCLC; however, structure and functional peculiarities of the remaining alleles have not been examined. According to our results, there is no association between LOH at this region, clinicopathological parameters and post-operating progression of disease. These results, however, are not contrary to the possibility that inactivation of putative TSG(s) may be involved in the early steps of tumour development.
In this study, MI was found in six cases (10.3%). Our results support two previous studies that showed low frequency of MI in NSCLC (2-6.5%) Fong et al, 1995b) . On the other hand, it differs from data by Shridhar et al (1994) , indicating MI for 34% tumour samples (mainly loci, mapped on 3p). This contradiction could be explained by the fact that various chromosomes were analysed in contrasting studies and different susceptibility of tested loci to MI may take place. It must be noted that there is an epidemiological and inheriting heterogeneity of analysed groups in different populations (Takagi et al, 1996) .
We have observed a trend towards a relationship between MI and advanced stage of disease. Although in hereditary tumours MI caused aberrations in mismatch repair genes such as the hMSH2 gene (Fishel et al, 1993) , for sporadic tumours the same association has not been always found (Zhu et al, 1996) . As far as MI is a form of whole genetic instability, this correlation with advanced stage of disease is not surprising.
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In conclusion, the study showed LOH at the regions Ipi 3. 1 and lp32-pter in nearly 50% of the tested NSCLCs and may suggest the location of possible tumour-suppressor genes of considerable importance in these regions. The last region has been identified with adverse clinical features by association of LOH. Refined mapping of these regions and cloning of the target gene(s) will be the next critical steps in the understanding of the biological importance of lp LOH in NSCLC development.
